| Literature DB >> 32145456 |
Stamatia Laidou1, Gregorio Alanis-Lobato2, Jan Pribyl3, Tamás Raskó4, Boris Tichy3, Kamil Mikulasek5, Maria Tsagiopoulou1, Jan Oppelt3, Georgia Kastrinaki6, Maria Lefaki7, Manvendra Singh4, Annika Zink8, Niki Chondrogianni7, Fotis Psomopoulos9, Alessandro Prigione8, Zoltán Ivics10, Sarka Pospisilova3, Petr Skladal3, Zsuzsanna Izsvák11, Miguel A Andrade-Navarro12, Spyros Petrakis13.
Abstract
Spinocerebellar ataxia type-1 (SCA1) is caused by an abnormally expanded polyglutamine (polyQ) tract in ataxin-1. These expansions are responsible for protein misfolding and self-assembly into intranuclear inclusion bodies (IIBs) that are somehow linked to neuronal death. However, owing to lack of a suitable cellular model, the downstream consequences of IIB formation are yet to be resolved. Here, we describe a nuclear protein aggregation model of pathogenic human ataxin-1 and characterize IIB effects. Using an inducible Sleeping Beauty transposon system, we overexpressed the ATXN1(Q82) gene in human mesenchymal stem cells that are resistant to the early cytotoxic effects caused by the expression of the mutant protein. We characterized the structure and the protein composition of insoluble polyQ IIBs which gradually occupy the nuclei and are responsible for the generation of reactive oxygen species. In response to their formation, our transcriptome analysis reveals a cerebellum-specific perturbed protein interaction network, primarily affecting protein synthesis. We propose that insoluble polyQ IIBs cause oxidative and nucleolar stress and affect the assembly of the ribosome by capturing or down-regulating essential components. The inducible cell system can be utilized to decipher the cellular consequences of polyQ protein aggregation. Our strategy provides a broadly applicable methodology for studying polyQ diseases.Entities:
Keywords: Ataxin-1; Oxidative stress; Polyglutamine; Protein network; Ribosome; Sleeping beauty transposon
Mesh:
Substances:
Year: 2020 PMID: 32145456 PMCID: PMC7058924 DOI: 10.1016/j.redox.2020.101458
Source DB: PubMed Journal: Redox Biol ISSN: 2213-2317 Impact factor: 11.799
Fig. 1Generation of Tet-On YFP-ATXN1(Q82) MSCs using a novel inducible SB transposon system. (A) Schematic overview of the Tet-On principle. In the absence of tetracycline, TetR protein dimers bind to the CMV/TetO2 promoter and suppress transgene expression. In the presence of tetracycline, TetR adopts a different conformation and loses its affinity for the CMV/TetO2 promoter allowing transgene expression. (B) Components of the Tet-On SB transposon system. The system is comprised of two pT2-based plasmids, a Tet-On Gateway compatible and a bicistronic TetR-neoR transposon. (C) Fluorescence microscopy of Tet-On YFP-ATXN1(Q82) MSCs in the absence (D0, left) or presence (D1, right) of Dox (scale bar = 25 μm). (D) Flow cytometry (histogram plot) of uninduced (blue color) and induced (green color) cells. (E) Immunoblot detection of transgene expression in extracts of uninduced and induced cells using anti-ATXN1 or anti-GFP antibodies. β-actin was used as a loading control. . (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2MSCs expressing YFP-ATXN1(Q82) accumulate insoluble IIBs. (A) Fluorescence microscopy of Tet-On YFP-ATXN1(Q82) MSCs at D2-D10. Nuclei are stained with DAPI (blue color) (scale bar = 10 μm). (B–C) Immunoblots for ATXN1 in B. SDS-PAGE and C. Filter retardation assays using extracts of uninduced or induced cells. β-actin was used as loading control. (D) Second derivative of the FTIR absorption spectrum of Tet-On YFP-ATXN1(Q82) MSCs at D2 or D10. Spectra were corrected after subtraction of the Venus MSCs spectrum. The D10 spectrum shows a peak at 1657 cm−1 indicative of α-helix conformation and three peaks at 1640, 1686 and 1700 cm−1, corresponding to coiled-coils, intra- and inter-molecular β-sheets in ATXN1(Q82). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 3Cellular effects of YFP-ATXN1(Q82) IIBs. (A) Detailed view of the cell nucleus. Cells at D0-D10 were fixed and visualized by AFM in hybrid mode (Quantitative Imaging). White arrows indicate natural nuclear content (nucleoli). The white scale bar in the right image is equal to 20 μm. Z-scaling of all images ranges from 85 to 190 mN/m (B–C) Percentages of (B) ROS and (C) CT-L proteasome activity in uninduced and induced Tet-On YFP-ATXN1(Q82) MSCs at D2, D5 and D10. ROS levels and CT-L activity of control cells (D0) were arbitrarily set to 100%. Error bars denote ±SEM (** p-value < 0.01, *** p-value < 0.001).
Fig. 4Detailed view of polyQ ATXN1 protein inclusions visualized in-situ. IIBs from Tet-On YFP-ATXN1(Q82) at D10 were immobilized on a plastic surface after lysis of cells in 0.1% SDS PBS. Measurements were performed in isotonic PBS by AFM hybrid mode imaging. Closer view of different parts of an IIB is shown below the main image in A–C. A-SM shows the distribution of stiffness over the area of image A. Inserted scale bars and Z-scale ranges are as follows: main image 3 μm/100 nm, (A) 1 μm/15 nm, (A-SM) 1 μm/3–130 MPa, (B) 300 nm/30 nm and (C) 750 nm/30 nm.
Pathway enrichment analysis of proteins detected in insoluble polyQ IIBs.
| Cytoskeletal regulation by Rho GTPase (P00016) | 12/70 | <0.0001 | TUBB2B; TUBB6; ACTC1; TUBB3; TUBB; CFL1; ARPC4-TTLL3; MYH9; PFN1; TUBB4B; MYH10; ACTG1 |
| Integrin signaling pathway (P00034) | 15/156 | <0.0001 | ITGB1; ARF1; ACTN1; COL12A1; FN1; ACTN4; ACTG1; COL1A1; COL3A1; COLA2; COL6A1; FLNA; FLNB; TLN1; VCL |
| Parkinson's disease (P00049) | 11/81 | <0.0001 | HSPA9; YWHAE; PSMA5; HSPA8; UCHL; HSPA5; YWHAQ; YWHAB; YWHAZ; YWHAG; PSMA7 |
| Huntington's disease (P00029) | 10/124 | <0.0001 | ARF4; TUBB6; TUBB2B; ARF1; ACTC1; TUBB3; TUBB; TUBB4B; GAPDH; ACTG1 |
| Glycolysis (P00024) | 6/17 | <0.0001 | TPI1; PKM; PGK1; ENO1; ALDOA; GAPDH |
Top five statistically significant enriched pathway terms and overlap of identified genes/proteins with the components of the pathway. The analysis was performed using the PANTHER database.
Fig. 5Transcriptional changes in Tet-On YFP-AXN1(Q82) MSCs containing IIBs. (A) Principal Component Analysis (PCA) of the expression vectors of the 3,984 genes specifically dysregulated in Tet-On YFP-AXN1(Q82) MSCs in four time-points according to their PC1 and 2 coordinates. Percentages (%) indicate the proportion of variance of analyzed data per axis. (B) Hierarchical clustering analysis and heatmap of ATXN1-DE genes between cells at D2, D5 or D10 vs D0 (|log2fold change| ≥ 1 and p-value < 0.05). Each row represents one gene and each column one sample. Figure also shows the absolute numbers of up- or down-regulated ATXN1-DE genes in each time point. (C) Venn diagram showing the overlap of ATXN1-DE genes per comparison (described in B). KEGG pathway enrichment analysis of ATXN1-DE genes at all time points (D2-D10) is also shown.
Pathway enrichment analysis of up- or down-regulated genes in Tet-On YFP-ATXN1(Q82) MSCs containing polyQ IIBs.
| ECM-receptor interaction_hsa04512 | 12/82 | >0.0001 | Ribosome_hsa03010 | 30/137 | >0.0001 |
| Focal adhesion_hsa04510 | 16/202 | >0.0001 | DNA replication_hsa03030 | 6/36 | >0.0001 |
| PI3K-Akt signaling pathway_hsa04151 | 18/341 | >0.0001 | Alzheimer's disease_hsa05010 | 10/168 | 0.0010 |
| Proteoglycans in cancer_hsa05205 | 13/203 | >0.0001 | Cell cycle_hsa04110 | 8/124 | 0.0018 |
| Rap1 signaling pathway_hsa04015 | 13/211 | >0.0001 | Oxidative phosphorylation_hsa00190 | 8/133 | 0.0028 |
| Regulation of actin cytoskeleton_hsa04810 | 12/214 | >0.0001 | Huntington's disease_hsa05016 | 9/193 | 0.0084 |
| Protein digestion and absorption_hsa04974 | 7/90 | 0.0001 | DNA replication_hsa03030 | 4/36 | 0.0003 |
| AGE-RAGE signaling pathway in diabetic complications_hsa04933 | 6/101 | 0.0008 | Cell cycle_hsa04110 | 7/124 | 0.0002 |
| PI3K-Akt signaling pathway_hsa04151 | 9/341 | 0.0114 | p53 signaling pathway_hsa04115 | 5/69 | 0.0004 |
| p53 signaling pathway_hsa04115 | 4/69 | 0.0064 | Axon guidance_hsa04360 | 6/127 | 0.0012 |
| Lysosome_hsa04142 | 5/123 | 0.0104 | Wnt signaling pathway_hsa04310 | 6/142 | 0.0020 |
| Transcriptional misregulation in cancer_hsa05202 | 6/180 | 0.0131 | MAPK signaling pathway_hsa04010 | 7/255 | 0.0095 |
Statistically significant enriched pathway terms for up- or down-regulated genes in the relevant comparisons (A. D2 versus D0 and B. D10 versus D2) and the overlap with the components of the pathway. The analysis was performed using the KEGG database.
Pathway enrichment analysis of down- and up-regulated genes in human SCA1 cerebellum and D10 Tet-On YFP-ATXN1(Q82) MSCs.
| Protein processing in endoplasmic reticulum_hsa04141 | 66/169 | >0.0001 | Ribosome_hsa03010 | 32/137 | >0.0001 |
| Spliceosome_hsa03040 | 52/134 | >0.0001 | Huntington's disease_hsa05016 | 12/193 | 0.0008 |
| RNA degradation_hsa03018 | 31/77 | >0.0001 | DNA replication_hsa03030 | 5/36 | 0.0009 |
| Cell cycle_hsa04110 | 41/124 | >0.0001 | Cell cycle_hsa04110 | 9/124 | 0.0012 |
| RNA transport_hsa03013 | 52/172 | >0.0001 | Alzheimer's disease_hsa05010 | 10/168 | 0.0029 |
| Proteasome_hsa03050 | 20/44 | >0.0001 | Parkinson's disease_hsa05012 | 9/142 | 0.0030 |
| Protein export_hsa03060 | 13/23 | >0.0001 | Non-alcoholic fatty liver disease (NAFLD)_hsa04932 | 9/151 | 0.0045 |
| Ubiquitin mediated proteolysis_hsa04120 | 42/137 | >0.0001 | Oxidative phosphorylation_hsa00190 | 8/133 | 0.0069 |
| FoxO signaling pathway_hsa04068 | 40/133 | >0.0001 | Nucleotide excision repair_hsa03420 | 4/47 | 0.0165 |
| DNA replication_hsa03030 | 15/36 | 0.0002 | Spliceosome_hsa03040 | 7/134 | 0.0227 |
| Non-homologous end-joining_hsa03450 | 8/13 | 0.0003 | Pyrimidine metabolism_hsa00240 | 6/105 | 0.0229 |
| mRNA surveillance pathway_hsa03015 | 28/91 | 0.0003 | Ubiquitin mediated proteolysis_hsa04120 | 7/137 | 0.0252 |
| Nucleotide excision repair_hsa03420 | 16/47 | 0.0018 | RNA transport_hsa03013 | 8/172 | 0.0285 |
| Oxidative phosphorylation_hsa00190 | 34/133 | 0.0029 | Fatty acid biosynthesis_hsa00061 | 2/13 | 0.029 |
| Ribosome_hsa03010 | 34/137 | 0.0049 | Base excision repair_hsa03410 | 3/33 | 0.0311 |
| Focal adhesion_hsa04510 | 20/202 | >0.0001 | Focal adhesion_hsa04510 | 17/202 | >0.0001 |
| Chronic myeloid leukemia_hsa05220 | 11/73 | 0.0001 | ECM-receptor interaction_hsa04512 | 11/82 | >0.0001 |
| Hippo signaling pathway_hsa04390 | 16/153 | 0.0001 | PI3K-Akt signaling pathway_hsa04151 | 17/341 | >0.0001 |
| Cell adhesion molecules (CAMs)_hsa04514 | 15/142 | 0.0002 | Proteoglycans in cancer_hsa05205 | 11/203 | >0.0001 |
| Notch signaling pathway_hsa04330 | 8/48 | 0.0003 | Protein digestion and absorption_hsa04974 | 8/90 | >0.0001 |
| AGE-RAGE signaling pathway in diabetic complications_hsa04933 | 11/101 | 0.0011 | Regulation of actin cytoskeleton_hsa04810 | 11/214 | 0.0002 |
| Proteoglycans in cancer_hsa05205 | 17/203 | 0.0012 | Pathways in cancer_hsa05200 | 15/397 | 0.0003 |
| Regulation of actin cytoskeleton_hsa04810 | 17/214 | 0.0021 | Rap1 signaling pathway_hsa04015 | 10/211 | 0.0006 |
| Long-term potentiation_hsa04720 | 8/66 | 0.0025 | Phagosome_hsa04145 | 7/154 | 0.0049 |
| ECM-receptor interaction_hsa04512 | 9/82 | 0.0028 | Leukocyte transendothelial migration_hsa04670 | 6/118 | 0.0053 |
| Inositol phosphate metabolism_hsa00562 | 8/71 | 0.0040 | Glioma_hsa05214 | 4/65 | 0.0114 |
| ErbB signaling pathway_hsa04012 | 9/87 | 0.0042 | AGE-RAGE signaling pathway in diabetic complications_hsa04933 | 5/101 | 0.0118 |
The table shows statistically significant enriched pathway terms for A. down- or B. up-regulated genes in the relevant comparisons and the overlap with the components of the pathway. The analysis was performed using the KEGG database.
Fig. 6ATXN1 IIBs dysregulate ribosome assembly and translation-associated protein interactions. (A) ATXN1-DE genes significantly dysregulated between D10 and D0 cells form a highly interconnected PPI network module (largest connected component or LCC) whose size (black arrow) is significantly greater than expected by chance. (B) The down-regulated members of this LCC play important roles in ribosome assembly and translation. By contrast, the up-regulated members of the LCC are involved in cellular organization functions and compartments. (C) The LCC of the constructed cerebellum-specific PPI network has a densely connected region formed almost entirely by ribosomal subunits and contains a significant number of proteins detected by MS in the insoluble IIBs at D10 (n = 33, p-value < 0.001). This depiction also highlights the interaction partners of ATXN1 in the LCC and human SCA1-DE genes (n = 109, p-value < 0.001, magenta color). Expression levels of each gene in the disease cell model are also shown. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Protein levels of LCC ribosome components in cells containing insoluble polyQ IIBs.
| Ataxin-1 | 9.05 | >0.001 | >0.001 | |
| Eukaryotic translation initiation factor 2 subunit 1 | −0.51 | >0.001 | 0.001 | |
| Eukaryotic translation initiation factor 3 subunit E | −0.53 | >0.001 | 0.001 | |
| Eukaryotic translation initiation factor 3 subunit L | −0.60 | >0.001 | 0.001 | |
| rRNA 2′-O-methyltransferase fibrillarin | −0.17 | 0.036 | 0.065 | |
| 60S ribosomal protein L4 | −0.50 | >0.001 | 0.001 | |
| 60S ribosomal protein L6 | −0.56 | >0.001 | 0.001 | |
| 60S ribosomal protein L7 | −0.63 | >0.001 | 0.001 | |
| 60S ribosomal protein L7a | −0.32 | 0.014 | 0.030 | |
| 60S ribosomal protein L10a | −0.60 | >0.001 | 0.001 | |
| 60S ribosomal protein L11 | −0.70 | >0.001 | 0.001 | |
| 60S ribosomal protein L22 | −0.63 | >0.001 | 0.001 | |
| 60S ribosomal protein L30 | −0.66 | >0.001 | 0.002 | |
| 60S ribosomal protein L35 | −0.65 | >0.001 | 0.001 | |
| 60S ribosomal protein L36 | −0.54 | >0.001 | 0.002 | |
| 60S ribosomal protein L37a | −0.50 | >0.001 | 0.002 | |
| 60S ribosomal protein L38 | −0.25 | 0.009 | 0.021 | |
| 60S acidic ribosomal protein P0 | −0.59 | >0.001 | >0.001 | |
| 60S acidic ribosomal protein P2 | −0.62 | >0.001 | 0.001 | |
| 40S ribosomal protein S3 | −0.73 | >0.001 | 0.001 | |
| 40S ribosomal protein S3a | −0.64 | >0.001 | 0.001 | |
| 40S ribosomal protein S4, X isoform | −0.61 | >0.001 | 0.001 | |
| 40S ribosomal protein S6 | −0.67 | >0.001 | 0.000 | |
| 40S ribosomal protein S8 | −0.63 | >0.001 | >0.001 | |
| 40S ribosomal protein S9 | −0.61 | >0.001 | 0.001 | |
| 40S ribosomal protein S13 | −0.62 | >0.001 | 0.001 | |
| 40S ribosomal protein S15a | −0.62 | >0.001 | 0.001 | |
| 40S ribosomal protein S16 | −0.45 | 0.002 | 0.006 | |
| 40S ribosomal protein S21 | −0.88 | >0.001 | 0.001 | |
| 40S ribosomal protein S25 | −0.64 | >0.001 | >0.001 | |
| 40S ribosomal protein S27 | −1.08 | >0.001 | >0.001 | |
| Ubiquitin-40S ribosomal protein S27a | 0.52 | >0.001 | 0.001 |
The table shows the log2fold change in the protein levels of LCC components which are related to protein synthesis.
Fig. 7Cellular events caused by the gradual formation of insoluble ATXN1(Q82) IIBs. Production of ATXN1(Q82) dysregulates ribosomal genes and causes oxidative and nucleolar stress at early stages of protein aggregation. Expanding IIBs (shown with green color) compress the nucleolus and sequester ribosomal proteins. Eventually, insoluble ATXN1(Q82) IIBs disrupt the biogenesis of ribosomes and cause cell necrosis. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)